Drugs / GLB-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06219356 | Jan 2024 → Jan 2026 overdue | non-Hodgkin lymphoma | Hangzhou GluBio Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06219356 ↗ |
| Route | Oral | “Administered orally according to the assigned treatment schedule.” NCT06219356 ↗ |